If Orexigen Disappears, Who's Left In The Obesity Market?
Orexigen, one of just five biopharma companies with an obesity product on the market, has become concerned about its ability to stay in business. Even so, the misfortune of several firms hasn't dissuaded others, including Novo Nordisk, from investing in the potentially large weight-loss market.
You may also be interested in...
Qsymia Webpage’s ‘3 Times Faster’ Weight-Loss Claims Draw US FDA Ire
Claims that Vivus' obesity drug helps patients lose weight faster than diet and exercise alone are false and misleading because the clinical studies were not designed to evaluate the rate of weight loss over time, Office of Prescription Drug Promotion says in untitled letter; Vivus says it is finalizing revisions to its promotions.
Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer
Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.
Smooth AdCom Passage Expected For Novo's Semaglutide Despite Retinopathy Queries
Novo Nordisk's Victoza follow-on semaglutide, forecast to become the third once-weekly GLP-1 product available on the highly competitive US diabetes market, is expected to secure a market-leading spot, by revenue, before 2025.